In the latest sign of a slump in consumer genetic testing, 23andMe is laying off 14% of its workforce amid falling sales of its DNA spit kits. The cut of about 100 jobs, which could be the company’s largest downsize yet, will mostly impact 23andMe’s operations teams, CEO Anne Wojcicki told CNBC on Thursday.
A company spokesperson, Christine Pai, told STAT in an email: “What I can confirm is that we are restructuring the consumer business, which impacts about 14% of employees. Our therapeutics business is not impacted. We’re also narrowing focus on the core businesses — consumer and therapeutics.”